Kidswell Bio Corporation (4584.T)
Tokyo · JPY · Healthcare · Biotechnology
¥149 (-1.32%) as of
Key statistics
- Market cap
- 7.40B
- Forward P/E
- 14.47
- EPS (TTM)
- -7.89
- Dividend yield
- 0.00%
- 52-week range
- 125.00 – 320.00
- Beta
- 1.12
- Revenue (TTM)
- 6.14B
- Profit margin
- -6.08%
- Analyst target
- ¥450
- Volume
- 116.50k
About Kidswell Bio Corporation
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Chuo, Japan
- Employees
- 32
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.